ZA200304100B - Lactam compounds and medicinal use thereof. - Google Patents

Lactam compounds and medicinal use thereof. Download PDF

Info

Publication number
ZA200304100B
ZA200304100B ZA200304100A ZA200304100A ZA200304100B ZA 200304100 B ZA200304100 B ZA 200304100B ZA 200304100 A ZA200304100 A ZA 200304100A ZA 200304100 A ZA200304100 A ZA 200304100A ZA 200304100 B ZA200304100 B ZA 200304100B
Authority
ZA
South Africa
Prior art keywords
group
substituent
groups
ring
acyl
Prior art date
Application number
ZA200304100A
Other languages
English (en)
Inventor
Yukio Iino
Takao Ikenoue
Nobuo Kondo
Hiroyuki Matsueda
Toshihiro Hatanaka
Ruysuke Hirama
Yoko Masuzawa
Fumio Ohta
Akiyo Yamazaki
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of ZA200304100B publication Critical patent/ZA200304100B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
ZA200304100A 2000-12-01 2003-05-27 Lactam compounds and medicinal use thereof. ZA200304100B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01

Publications (1)

Publication Number Publication Date
ZA200304100B true ZA200304100B (en) 2004-08-22

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200304100A ZA200304100B (en) 2000-12-01 2003-05-27 Lactam compounds and medicinal use thereof.

Country Status (26)

Country Link
US (3) US7153850B2 (cg-RX-API-DMAC7.html)
EP (1) EP1346993B1 (cg-RX-API-DMAC7.html)
JP (2) JP3826400B2 (cg-RX-API-DMAC7.html)
KR (1) KR100826818B1 (cg-RX-API-DMAC7.html)
CN (2) CN1269818C (cg-RX-API-DMAC7.html)
AT (1) ATE446297T1 (cg-RX-API-DMAC7.html)
AU (3) AU1850202A (cg-RX-API-DMAC7.html)
BG (1) BG107857A (cg-RX-API-DMAC7.html)
BR (1) BR0115852A (cg-RX-API-DMAC7.html)
CA (1) CA2430124C (cg-RX-API-DMAC7.html)
CZ (1) CZ20031520A3 (cg-RX-API-DMAC7.html)
DE (1) DE60140270D1 (cg-RX-API-DMAC7.html)
ES (1) ES2331299T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0400806A3 (cg-RX-API-DMAC7.html)
IL (1) IL156158A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004876A (cg-RX-API-DMAC7.html)
NO (1) NO325401B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ526164A (cg-RX-API-DMAC7.html)
PL (1) PL362835A1 (cg-RX-API-DMAC7.html)
RU (1) RU2287530C2 (cg-RX-API-DMAC7.html)
SK (1) SK6582003A3 (cg-RX-API-DMAC7.html)
TW (1) TWI241302B (cg-RX-API-DMAC7.html)
UA (1) UA76969C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002044180A1 (cg-RX-API-DMAC7.html)
YU (1) YU42603A (cg-RX-API-DMAC7.html)
ZA (1) ZA200304100B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
WO2005042536A1 (ja) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
CA2553329A1 (en) 2004-01-14 2005-07-28 Ajinomoto Co., Inc. New fused polycyclic compounds
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
JP5056412B2 (ja) 2005-04-28 2012-10-24 味の素株式会社 新規ラクタム化合物
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
EP3238723B1 (en) * 2014-12-22 2020-02-05 EA Pharma Co., Ltd. Drug for treating disorders of corneal epithelium
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
TWI820289B (zh) * 2019-01-23 2023-11-01 醣解生醫股份有限公司 β-內醯胺類化合物或其鹽於長效預防或治療葡萄糖代謝失調之用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
ES2229523T3 (es) 1997-07-30 2005-04-16 Wyeth Agonistas triciclicos de la vasopresina.
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
MXPA05008363A (es) * 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.

Also Published As

Publication number Publication date
HUP0400806A2 (hu) 2004-07-28
NO325401B1 (no) 2008-04-21
CA2430124C (en) 2011-01-11
PL362835A1 (en) 2004-11-02
ATE446297T1 (de) 2009-11-15
SK6582003A3 (en) 2003-09-11
CZ20031520A3 (cs) 2003-10-15
US7326701B2 (en) 2008-02-05
IL156158A0 (en) 2003-12-23
AU2002218502B2 (en) 2006-09-21
US7153850B2 (en) 2006-12-26
JPWO2002044180A1 (ja) 2004-04-02
CN1911915A (zh) 2007-02-14
US20040048847A1 (en) 2004-03-11
YU42603A (sh) 2006-03-03
KR100826818B1 (ko) 2008-05-02
NO20032439L (no) 2003-07-18
AU2006241377A1 (en) 2006-12-14
UA76969C2 (en) 2006-10-16
NO20032439D0 (no) 2003-05-28
US7632830B2 (en) 2009-12-15
AU1850202A (en) 2002-06-11
US20080096862A1 (en) 2008-04-24
CA2430124A1 (en) 2002-06-06
JP4505753B2 (ja) 2010-07-21
WO2002044180A1 (en) 2002-06-06
MXPA03004876A (es) 2004-01-27
BG107857A (bg) 2004-06-30
EP1346993A4 (en) 2005-12-21
CN100577651C (zh) 2010-01-06
EP1346993B1 (en) 2009-10-21
HUP0400806A3 (en) 2007-11-28
KR20030051893A (ko) 2003-06-25
ES2331299T3 (es) 2009-12-29
CN1487940A (zh) 2004-04-07
NZ526164A (en) 2004-09-24
CN1269818C (zh) 2006-08-16
JP3826400B2 (ja) 2006-09-27
US20060189597A1 (en) 2006-08-24
TWI241302B (en) 2005-10-11
RU2287530C2 (ru) 2006-11-20
EP1346993A1 (en) 2003-09-24
DE60140270D1 (de) 2009-12-03
BR0115852A (pt) 2003-12-23
JP2006213732A (ja) 2006-08-17
AU2006241377B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
RU2412192C2 (ru) Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2
TWI699359B (zh) 4h-吡咯[3,2-c]吡啶-4-酮衍生物
TWI242435B (en) Pyrrolo[2,3d]pyrimidine compositions and their use
JP2022504601A (ja) Mst1キナーゼ阻害剤及びその使用
AU2008265600B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
BR112020025073A2 (pt) moduladores de montagem de capsídeo da hepatite b
TW201014846A (en) Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
CN109641874A (zh) 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN102971317A (zh) 四氢-吡啶并-嘧啶衍生物
EP2861599A1 (en) Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
AU2013243671A1 (en) Methods for improving diaphragm function
WO2010097332A1 (de) Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
JP2008513498A5 (cg-RX-API-DMAC7.html)
RU2008148547A (ru) Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением
CN107206004A (zh) 靶向盘状结构域受体1的小分子抑制剂及其用途
CN110167933A (zh) 作为αV整联蛋白抑制剂的唑酰胺和胺
CN1121220C (zh) 稠合哒嗪系化合物的勃起机能不全症治疗剂
US7153850B2 (en) Lactam compounds and pharmaceutical use thereof
ES3063045T3 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
AU2004210268A1 (en) Therapeutic agents for diabetes
BRPI0711632A2 (pt) combinação e composição farmacêutica compreendendi 40-o-(2-hidroxietil)-rapamicina e uma segunda substáncia fármaco, e uso da referida combinação
RU2440346C2 (ru) Способ и композиция для стимуляции нейрогенеза и ингибирования дегенерации нейронов
RU2005100761A (ru) Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов
ES2963508T3 (es) Derivados de 5-hidroxi-7-oxabiciclo[2.2.1]heptano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
CN106478631A (zh) 长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法